Insight

Alizée Camps Maléa and Cédric Draulans

Oct 12, 2024, 19:36

5 Year Results of the Hypo-FLAME Trial

Alizée Camps Maléa, Radiation oncologist at Gustave Roussy and President of the French Society of Young Radiation Oncologists at SFjRO, shared a recent article by Cédric Draulans, Scientific Researcher in Radiation Oncology at KU Leuven, on X:

“Hypo-FLAME phase 2.

Intermediate & high-risk prostate cancer.

SBRT 35 Gy to the whole prostate gland in 5 weekly fractions & focal boosts to the intraprostatic tumor 50 Gy.

5-year: bDFS 93% & grade 2+ tox GU 12% GI 4%.”

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial

Authors: Cédric Draulans, Karin Haustermans, Floris J. Pos, Uulke A. van der Heide, Lisa De Cock, Jochem van der Voort van Zyp, Hans De Boer, Robert J. Smeenk, Martina Kunze-Busch, Evelyn M Monninkhof, Sofie Isebaert and Linda G.W. Kerkmeije

cancer Cédric Draulans Evelyn M. Monninkhof Floris J. Pos Gustave Roussy hypo-FLAME trial intraprostatic tumor Karin Haustermans KU Leuven Linda G.W. Kerkmeije Martina Kunze-Busch OncoDaily oncologyu prostate cancer radiotherapy Robert J. Smeenk SFjRO Sofie Isebaert Uulke A. van der Heide

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer